Biological evaluation of the novel 3,3′-((4-nitrophenyl)methylene)bis(4-hydroxy-2H-chromen-2-one) derivative as potential anticancer agents via the selective induction of reactive oxygen species-mediated apoptosis
Cellular Signalling · 2023
DOI: 10.1016/j.cellsig.2023.110876 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2023. Verfasst von Sayanta Dutta und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Medicine, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata 700054, India. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 91 Literaturangaben.
Abstract (Originalsprache)
Selective initiation of programmed cell death in cancer cells than normal cells is reflected as an attractive chemotherapeutic strategy. In the current study, a series of synthetic bis-coumarin derivatives were synthesized possessing reactive oxygen species (ROS) modulating functional groups and examined in four cancerous and two normal cell lines for their cytotoxic ability using MTT assay. Among these compounds, 3 l emerged as the most promising derivative in persuading apoptosis in human renal carcinoma cells (SKRC-45) among diverse cancer cell lines. 3 l causes significantly less cytotoxicity to normal kidney cells compared to cisplatin. This compound was able to induce apoptosis and cell-cycle arrest by modulating the p53 mediated apoptotic pathways via the generation of ROS, decreasing mitochondrial membrane potential, and causing DNA fragmentation. Unlike cisplatin, the 3 l derivative was found to inhibit the nuclear localisation of NF-κB in SKRC-45 cells. It was also found to reduce the proliferation, survival and migration ability of SKRC-45 cells by downregulating COX-2/ PTGES2 cascade and MMP-2. In an in vivo tumor model, 3 l showed an anticancer effect by reducing the mean tumor mass, volume and inducing caspase-3 activation, without affecting kidney function. Further studies are needed to establish 3 l as a promising anti-cancer drug candidate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Molecular Medicine, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata 700054, India.
- Laboratory of Natural Products and Organic Synthesis, Department of Chemistry, Visva-Bharati (a Central University), Santiniketan 731 235, West Bengal, India.
- Division of Molecular Medicine, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata 700054, India. Electronic address: parames@jcbose.ac.in.
Zitieren
APA
Dutta, S., Mahalanobish, S., Saha, S., Mandal, M., Begam, S., Sadhukhan, P., Ghosh, S., Brahmachari, G., & Sil, P. C. (2023). Biological evaluation of the novel 3,3′-((4-nitrophenyl)methylene)bis(4-hydroxy-2H-chromen-2-one) derivative as potential anticancer agents via the selective induction of reactive oxygen species-mediated apoptosis. Cellular Signalling. https://doi.org/10.1016/j.cellsig.2023.110876
Vancouver
Dutta S, Mahalanobish S, Saha S, Mandal M, Begam S, Sadhukhan P, et al. Biological evaluation of the novel 3,3′-((4-nitrophenyl)methylene)bis(4-hydroxy-2H-chromen-2-one) derivative as potential anticancer agents via the selective induction of reactive oxygen species-mediated apoptosis. Cellular Signalling. 2023. doi:10.1016/j.cellsig.2023.110876
BibTeX
@article{Dutta2023,
author = {Dutta, Sayanta and Mahalanobish, Sushweta and Saha, Sukanya and Mandal, Mullicka and Begam, Sanchari and Sadhukhan, Pritam and Ghosh, Sumit and Brahmachari, Goutam and Sil, Parames C},
title = {Biological evaluation of the novel 3,3′-((4-nitrophenyl)methylene)bis(4-hydroxy-2H-chromen-2-one) derivative as potential anticancer agents via the selective induction of reactive oxygen species-mediated apoptosis},
journal = {Cellular Signalling},
year = {2023},
doi = {10.1016/j.cellsig.2023.110876}
}
EUVIMED